24 February 2020
: Case report
A Case of Fournier’s Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Rare disease, Adverse events of drug therapy , Educational Purpose (only if useful for a systematic review or synthesis)
Ali Elbeddini1EF*, Jodi Gallinger2E, Michelle Davey3CD, Stephane Brassard4D, Mohammed Gazarin5BCEF, Frida Plourde6F, Ahmed Aly1CDOI: 10.12659/AJCR.920115
Am J Case Rep 2020; 21:e920115
Abstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of antihyperglycemic medications associated with an increased risk of urinary and genital infections due to their glycosuric effects. In 2018, the FDA issued a safety alert warning that multiple cases of Fournier’s Gangrene (FG), a severe genital infection, had been reported in patients taking SGLT2 inhibitors.
CASE REPORT: We present a case of 72-year-old male with type II diabetes mellitus who developed FG while taking the SGLT2 inhibitor canagliflozin. Besides diabetes and canagliflozin use, his other risk factors were his age, gender, and remote history of radiotherapy for prostate cancer. He presented to the Emergency Department (ED) multiple times complaining of rectal pain and was admitted for a possible diagnosis of prostatitis. During his stay, he developed leukocytosis, his pain worsened, and examination of the perianal area was consistent with FG. He was treated with multiple surgical debridement procedures and broad-spectrum antibiotics; the source of infection was determined to be a perianal abscess. He stayed in the hospital for 1 month and was discharged home with outpatient wound care and vacuum dressing changes. Canagliflozin was discontinued during the hospital stay.
CONCLUSIONS: Due to the possible association of FG with SGLT2 inhibitors, patients who present with signs and symptoms consistent with FG should be examined for possible FG and treated promptly.
Keywords: Fasciitis, Necrotizing, Fournier Gangrene, Sodium-Glucose Transporter 2, Aged, Anal Canal, Anti-Bacterial Agents, Canagliflozin, Combined Modality Therapy, Debridement, Diabetes Mellitus, Type 2, Male, Perineum, Sodium-Glucose Transporter 2 Inhibitors
SARS-CoV-2/COVID-19
19 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936370
17 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936651
13 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936589
13 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936574
In Press
24 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936600
23 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.935148
23 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936704
20 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936826
Most Viewed Current Articles
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
17 Feb 2022 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
19 Feb 2022 : Case report
DOI :10.12659/AJCR.935355
Am J Case Rep 2022; 23:e935355